Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.

FOLDยทNASDAQ

$14.49

+0.0000%
HealthcareBiotechnology

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$4.55B
EPS-0.0879
P/E Ratio-164.85
Earnings Date05/07/2026

No Dividend Yield Data

FOLD has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

FOLD has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

FOLD has not reported any net dividends paid values in the available annual periods.

Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. Dividend History

FOLD ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

FOLD Dividend Payment History

FOLD ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
fold

Amicus Therapeutics, Inc. Payout Ratio Analysis

FOLD ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-27.11M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.

Sustainability
Fair

Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.